Clinical Focus Leverage Arvinas’ PROTAC degradation platform and ongoing clinical programs (vepdegestrant, ARV-393, ARV-102) to position strategic partnerships or co-development opportunities with pharma companies seeking differentiated oncology and neurology assets.

Pipeline Optimization Align BD outreach with Arvinas’ shift toward internal development in neurology and oncology while seeking partners for assets that require broader resources, presenting a clear path for collaboration on later-stage or global development.

Financial Signals Arvinas recently highlighted quarterly results and a focus on selective investment; potential sales conversations can emphasize financing-ready partnerships, licensing deals, or milestone-driven collaborations aligned with their expected near-term financial updates.

Strategic Partnerships Highlight opportunities for co-development, licensing, or research collaborations around PROTAC technologies with external entities to augment Arvinas’ pipeline while reducing time-to-market and resource burden for both sides.

Impact & Engagement Capitalize on Arvinas’ demonstrated engagement with investors and the community, offering partnerships that incorporate patient-centric outcomes, real-world data collaborations, and joint advocacy or STEM outreach programs to bolster sponsor-community alignment.